Jonathan Alspaugh - 23 Feb 2023 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)

Role
Chief Financial Officer
Signature
/s/ James Kastenmayer, by power of attorney
Issuer symbol
SYRE
Transactions as of
23 Feb 2023
Net transactions value
$0
Form type
4
Filing time
24 Feb 2023, 17:20:36 UTC
Previous filing
25 Aug 2022
Next filing
30 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Employee Stock Option (right to buy) Award $0 +640,000 $0.000000 640,000 23 Feb 2023 Common Stock 640,000 $0.4400 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 23, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.